{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:50:12Z","timestamp":1790686212681,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2009,4,21]],"date-time":"2009-04-21T00:00:00Z","timestamp":1240272000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1007\/s11523-009-0110-4","type":"journal-article","created":{"date-parts":[[2009,4,20]],"date-time":"2009-04-20T08:40:29Z","timestamp":1240216829000},"page":"99-105","source":"Crossref","is-referenced-by-count":70,"title":["Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors"],"prefix":"10.1007","volume":"4","author":[{"given":"Kevin","family":"Kelly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronan","family":"Swords","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devalingam","family":"Mahalingam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swaminathan","family":"Padmanabhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis J.","family":"Giles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,4,21]]},"reference":[{"issue":"23","key":"110_CR1","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ et al (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355(23):2408\u20132417","journal-title":"N Engl J Med"},{"issue":"2","key":"110_CR2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","volume":"2","author":"NP Shah","year":"2002","unstructured":"Shah NP et al (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2(2):117\u2013125","journal-title":"Cancer Cell"},{"issue":"5531","key":"110_CR3","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre ME et al (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293(5531):876\u2013880","journal-title":"Science"},{"issue":"11","key":"110_CR4","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1002\/cncr.22661","volume":"109","author":"E Jabbour","year":"2007","unstructured":"Jabbour E et al (2007) Current and emerging treatment options in chronic myeloid leukemia. Cancer 109(11):2171\u20132181","journal-title":"Cancer"},{"issue":"12","key":"110_CR5","doi-asserted-by":"crossref","first-page":"913","DOI":"10.7326\/0003-4819-145-12-200612190-00008","volume":"145","author":"HM Kantarjian","year":"2006","unstructured":"Kantarjian HM et al (2006) New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med 145(12):913\u2013923","journal-title":"Ann Intern Med"},{"issue":"12","key":"110_CR6","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1182\/blood-2006-11-056028","volume":"109","author":"H Kantarjian","year":"2007","unstructured":"Kantarjian H et al (2007) Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 109(12):5143\u20135150","journal-title":"Blood"},{"issue":"24","key":"110_CR7","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","volume":"354","author":"M Talpaz","year":"2006","unstructured":"Talpaz M et al (2006) Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354(24):2531\u20132541","journal-title":"N Engl J Med"},{"issue":"5682","key":"110_CR8","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","volume":"305","author":"NP Shah","year":"2004","unstructured":"Shah NP et al (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305(5682):399\u2013401","journal-title":"Science"},{"issue":"20","key":"110_CR9","doi-asserted-by":"crossref","first-page":"9185","DOI":"10.1158\/0008-5472.CAN-05-1731","volume":"65","author":"S Nam","year":"2005","unstructured":"Nam S et al (2005) Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 65(20):9185\u20139189","journal-title":"Cancer Res"},{"issue":"6","key":"110_CR10","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","volume":"109","author":"A Hochhaus","year":"2007","unstructured":"Hochhaus A et al (2007) Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 109(6):2303\u20132309","journal-title":"Blood"},{"issue":"19","key":"110_CR11","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","volume":"26","author":"NP Shah","year":"2008","unstructured":"Shah NP et al (2008) Intermittent target inhibition with dasatinib 100\u00a0mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 26(19):3204\u20133212","journal-title":"J Clin Oncol"},{"issue":"25","key":"110_CR12","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1200\/JCO.2007.12.0329","volume":"25","author":"A Quintas-Cardama","year":"2007","unstructured":"Quintas-Cardama A et al (2007) Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 25(25):3908\u20133914","journal-title":"J Clin Oncol"},{"issue":"10","key":"110_CR13","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","volume":"110","author":"HM Kantarjian","year":"2007","unstructured":"Kantarjian HM et al (2007) Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110(10):3540\u20133546","journal-title":"Blood"},{"issue":"8","key":"110_CR14","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1164\/rccm.200705-715CR","volume":"176","author":"A Bergeron","year":"2007","unstructured":"Bergeron A et al (2007) Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. Am J Respir Crit Care Med 176(8):814\u2013818","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"110_CR15","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1365-2141.2008.07108.x","volume":"141","author":"H Lavallade de","year":"2008","unstructured":"de Lavallade H et al (2008) Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis. Br J Haematol 141(5):745\u2013747","journal-title":"Br J Haematol"},{"issue":"11","key":"110_CR16","first-page":"4270","volume":"112","author":"D Kim","year":"2008","unstructured":"Kim D et al (2008) Pleural effusion in dasatinib-treated chronic myeloid leukemia patients after imatinib failure. ASH Annual Meeting Abstracts 112(11):4270","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"12","key":"110_CR17","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1038\/leu.2008.221","volume":"22","author":"J Cortes","year":"2008","unstructured":"Cortes J et al (2008) Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia 22(12):2176\u20132183","journal-title":"Leukemia"},{"issue":"2","key":"110_CR18","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/cncr.22757","volume":"110","author":"EM Posadas","year":"2007","unstructured":"Posadas EM et al (2007) A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: a phase II clinical study with proteomic profiling. Cancer 110(2):309\u2013317","journal-title":"Cancer"},{"issue":"27","key":"110_CR19","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","volume":"47","author":"LJ Lombardo","year":"2004","unstructured":"Lombardo LJ et al (2004) Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 47(27):6658\u20136661","journal-title":"J Med Chem"},{"issue":"1","key":"110_CR20","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0022-3565(24)38879-2","volume":"295","author":"E Buchdunger","year":"2000","unstructured":"Buchdunger E et al (2000) Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295(1):139\u2013145","journal-title":"J Pharmacol Exp Ther"},{"issue":"13","key":"110_CR21","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1158\/1078-0432.CCR-07-5015","volume":"14","author":"MW Deininger","year":"2008","unstructured":"Deininger MW (2008) Nilotinib. Clin Cancer Res 14(13):4027\u20134031","journal-title":"Clin Cancer Res"},{"issue":"4","key":"110_CR22","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1152\/physrev.1999.79.4.1283","volume":"79","author":"CH Heldin","year":"1999","unstructured":"Heldin CH, Westermark B (1999) Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79(4):1283\u20131316","journal-title":"Physiol Rev"},{"issue":"5323","key":"110_CR23","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1126\/science.277.5323.242","volume":"277","author":"P Lindahl","year":"1997","unstructured":"Lindahl P et al (1997) Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 277(5323):242\u2013245","journal-title":"Science"},{"issue":"5","key":"110_CR24","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1200\/JCO.2005.01.032","volume":"23","author":"GC Jayson","year":"2005","unstructured":"Jayson GC et al (2005) Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume. J Clin Oncol 23(5):973\u2013981","journal-title":"J Clin Oncol"},{"issue":"10","key":"110_CR25","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1158\/1535-7163.MCT-08-0013","volume":"7","author":"SM Wilhelm","year":"2008","unstructured":"Wilhelm SM et al (2008) Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 7(10):3129\u20133140","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"110_CR26","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1634\/theoncologist.12-4-426","volume":"12","author":"D Strumberg","year":"2007","unstructured":"Strumberg D et al (2007) Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 12(4):426\u2013437","journal-title":"Oncologist"},{"issue":"7","key":"110_CR27","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1096\/fj.01-0700com","volume":"16","author":"AD Laird","year":"2002","unstructured":"Laird AD et al (2002) SU6668 inhibits Flk-1\/KDR and PDGFR{beta} in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice. FASEB J 16(7):681\u2013690","journal-title":"FASEB J"},{"issue":"7","key":"110_CR28","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/sj.onc.1209855","volume":"26","author":"Y Wallez","year":"2007","unstructured":"Wallez Y et al (2007) Src kinase phosphorylates vascular endothelial-cadherin in response to vascular endothelial growth factor: identification of tyrosine 685 as the unique target site. Oncogene 26(7):1067\u20131077","journal-title":"Oncogene"},{"issue":"4","key":"110_CR29","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S1097-2765(00)80213-0","volume":"4","author":"F Luton","year":"1999","unstructured":"Luton F et al (1999) The SRC family protein tyrosine kinase p62yes controls polymeric IgA transcytosis in vivo. Mol Cell 4(4):627\u2013632","journal-title":"Mol Cell"},{"issue":"12","key":"110_CR30","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","volume":"110","author":"U Rix","year":"2007","unstructured":"Rix U et al (2007) Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 110(12):4055\u20134063","journal-title":"Blood"},{"issue":"6","key":"110_CR31","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1165\/rcmb.2005-0236OC","volume":"33","author":"W Matsuyama","year":"2005","unstructured":"Matsuyama W et al (2005) Involvement of discoidin domain receptor 1 in the deterioration of pulmonary sarcoidosis. Am J Respir Cell Mol Biol 33(6):565\u2013573","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"5","key":"110_CR32","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1183\/09031936.01.17509690","volume":"17","author":"O Sakamoto","year":"2001","unstructured":"Sakamoto O et al (2001) Expression of discoidin domain receptor 1 tyrosine kinase on the human bronchial epithelium. Eur Respir J 17(5):969\u2013974","journal-title":"Eur Respir J"},{"key":"110_CR33","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1146\/annurev.immunol.22.012703.104743","volume":"23","author":"LJ Berg","year":"2005","unstructured":"Berg LJ et al (2005) Tec family kinases in T lymphocyte development and function. Annu Rev Immunol 23:549\u2013600","journal-title":"Annu Rev Immunol"},{"key":"110_CR34","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.0105-2896.2005.00225.x","volume":"203","author":"JM Lindvall","year":"2005","unstructured":"Lindvall JM et al (2005) Bruton's tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling. Immunol Rev 203:200\u2013215","journal-title":"Immunol Rev"},{"issue":"3","key":"110_CR35","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/jlb.65.3.286","volume":"65","author":"Y Kawakami","year":"1999","unstructured":"Kawakami Y et al (1999) Functions of Bruton's tyrosine kinase in mast and B cells. J Leukoc Biol 65(3):286\u2013290","journal-title":"J Leukoc Biol"},{"issue":"11","key":"110_CR36","first-page":"573","volume":"112","author":"S Mustjoki","year":"2008","unstructured":"Mustjoki S et al (2008) Clonal expansion of T\/NK-Cells during tyrosine kinase inhibitor dasatinib therapy. ASH Annual Meeting Abstracts 112(11):573","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"11","key":"110_CR37","first-page":"2938","volume":"110","author":"S Mustjoki","year":"2007","unstructured":"Mustjoki S et al (2007) Clonal large granular lymphocyte (LGL) expansion associated with dasatinib therapy. ASH Annual Meeting Abstracts 110(11):2938","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"14","key":"110_CR38","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ et al (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344(14):1031\u20131037","journal-title":"N Engl J Med"},{"key":"110_CR39","first-page":"4271","volume":"112","author":"PD Coutre le","year":"2008","unstructured":"le Coutre PD, 11 et al (2008) Occurrence of pleural\/pericardial effusions in Ph + CML patients failing prior tyrosine kinase inhibitors (TKI) before starting nilotinib\u2014retrospective analysis upon entry into the nilotinib compassionate use program. ASH Annual Meeting Abstracts 112:4271","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"1","key":"110_CR40","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1600-0609.2004.00347.x","volume":"74","author":"M Breccia","year":"2005","unstructured":"Breccia M et al (2005) Pleural-pericardic effusion as uncommon complication in CML patients treated with Imatinib. Eur J Haematol 74(1):89\u201390","journal-title":"Eur J Haematol"},{"issue":"2","key":"110_CR41","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/ajh.10186","volume":"71","author":"JC Barton","year":"2002","unstructured":"Barton JC et al (2002) Cardiac tamponade associated with imatinib mesylate therapy of chronic myelogenous leukemia. Am J Hematol 71(2):139\u2013140","journal-title":"Am J Hematol"},{"issue":"17","key":"110_CR42","doi-asserted-by":"crossref","first-page":"5325","DOI":"10.1158\/1078-0432.CCR-08-0308","volume":"14","author":"M Hazarika","year":"2008","unstructured":"Hazarika M et al (2008) Tasigna for chronic and accelerated phase Philadelphia chromosome\u2014positive chronic myelogenous leukemia resistant to or intolerant of imatinib. Clin Cancer Res 14(17):5325\u20135331","journal-title":"Clin Cancer Res"},{"issue":"2","key":"110_CR43","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","volume":"7","author":"E Weisberg","year":"2005","unstructured":"Weisberg E et al (2005) Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7(2):129\u2013141","journal-title":"Cancer Cell"},{"issue":"23","key":"110_CR44","doi-asserted-by":"crossref","first-page":"11314","DOI":"10.1158\/0008-5472.CAN-06-1199","volume":"66","author":"M Puttini","year":"2006","unstructured":"Puttini M et al (2006) In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl + neoplastic cells. Cancer Res 66(23):11314\u201311322","journal-title":"Cancer Res"},{"issue":"11","key":"110_CR45","first-page":"1098","volume":"112","author":"J Cortes","year":"2008","unstructured":"Cortes J et al (2008) Efficacy and safety of bosutinib (SKI-606) in patients with chronic phase (CP) Ph + chronic myelogenous leukemia (CML) with resistance or intolerance to imatinib. ASH Annual Meeting Abstracts 112(11):1098","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"6","key":"110_CR46","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/leu.2008.84","volume":"22","author":"A Hochhaus","year":"2008","unstructured":"Hochhaus A et al (2008) Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 22(6):1200\u20131206","journal-title":"Leukemia"},{"issue":"11","key":"110_CR47","first-page":"182","volume":"112","author":"J Cortes","year":"2008","unstructured":"Cortes J et al (2008) Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP). ASH Annual Meeting Abstracts 112(11):182","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"11","key":"110_CR48","first-page":"181","volume":"112","author":"G Rosti","year":"2008","unstructured":"Rosti G et al (2008) High and early rates of cytogenetic and molecular response with nilotinib 800\u00a0mg daily as first line treatment of Ph-positive chronic myeloid leukemia in chronic phase: results of a phase II trial of the GIMEMA CML Working Party. ASH Annual Meeting Abstracts 112(11):181","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"11","key":"110_CR49","first-page":"4586","volume":"110","author":"J Stephens","year":"2007","unstructured":"Stephens J et al (2007) The cost of managing pleural effusion associated with dasatinib in CML patients post imatinib failure. ASH Annual Meeting Abstracts 110(11):4586","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"5","key":"110_CR50","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/ng1343","volume":"36","author":"Y Hu","year":"2004","unstructured":"Hu Y et al (2004) Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet 36(5):453\u2013461","journal-title":"Nat Genet"},{"issue":"11","key":"110_CR51","first-page":"2161","volume":"108","author":"J Cortes","year":"2006","unstructured":"Cortes J et al (2006) Dasatinib (SPRYCEL\u00ae) in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in chronic phase (CML-CP). ASH Annual Meeting Abstracts 108(11):2161","journal-title":"ASH Annual Meeting Abstracts"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-009-0110-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11523-009-0110-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-009-0110-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T02:37:33Z","timestamp":1739068653000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11523-009-0110-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,21]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["110"],"URL":"https:\/\/doi.org\/10.1007\/s11523-009-0110-4","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,21]]}}}